Лікування методом перитонеального діалізу хворих на хронічну хворобу нирок V стадії адаптована клінічна настанова, заснована на доказах

Література:

1. 
   Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999;19(6):526-33.
   
2. 
   Buijsen CGM, Struijk DG, Huijgen AJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients Perit Dial Int 1996; 16: 497–504.
   
3. 
   Chen S-Y, Chen T-W, Lin S-H, Chen C-J, Yu Y-C, Kin C-H. Does previous abdominal surgery increase postoperative complication rates in continuous ambulatory peritoneal dialysis Perit Dial Int 2007; 27: 557-559.
   
4. 
   Clinical Practice Guidelines Peritoneal Dialysis. – UK Renal Association, 5th Edition, 2009-2012.
   
5. 
   Coles GA, Gokal R, Ogg C et al. A randomized controlled trial of a bicarbonate and a bicarbonate/lactate containing dialysis solution in CAPD. Perit Dial Int 1997; 17: 48–51.
   
6. 
   Davenport A, Goel S, MacKenzie JC. Audit of the use of calcium carbonate as phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1992; 7: 632–635.
   
7. 
   Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on Peritoneal Dialysis. J Am Soc Nephrol 2001;12(5):1046-51.
   
8. 
   Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004;66:2437-45.
   
9. 
   Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9: 41–45.
   
10. 
    European Best Practice Guidelines for Peritoneal Dialysis. – Nephrol. Dial. Transplant. – 2005. – V. 20. – Suppl. 9.
    
11. 
    Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J, and the Bicarbonate CAPD Cooperative Group. A randomized multicenter long-term clinical study comparing a bicarbonate buffered CAPD solution with the standard lactate buffered CAPD solution. Kidney Int 1998; 54: 1731–1738.
    
12. 
    Gotloib L, Shostak A, Waisbrut V, Kushnier R. High glucose induces a hypertrophic, senescent mesothelial cell phenotype after long in vivo exposure. Nephron 1999; 82:164–173.
    
13. 
    Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Low calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219–1225.
    
14. 
    Imholz ALT, Brown CB, Koomen GCM, Arisz L, Krediet RT. The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 1993; 9: 25–30.
    
15. 
    Johnson DW, Rigby RJ, McIntyre HB, Brown A, Freeman J. A randomized trial comparing 1.25 mmol/1 calcium dialysate to 1.75 mmol/1 calcium dialysate in CAPD patients. Nephrol Dial Transplant 1996; 11: 88–93.
    
16. 
    Jorres A, Bender TO, Finn A, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998;54(6):2184-93.
    
17. 
    Jörres A, Topley N, Steenweg L, Müller C, Köttgen E, Gahl GM. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992;12(1-2):80-5.
    
18. 
    Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148–1157.
    
19. 
    Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64(6):2222-8.
    
20. 
    Kwong MBL, Lee JSK, Chan MK. Transperitoneal calcium and magnesium transfer during an 8-hour dialysis. Perit Dial Bull 1987; 7: 85–89.
    
21. 
    Liberek T, Topley N, Jorres A, et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993;65(2):260-5.
    
22. 
    Lindholm B, Bergstrom J. Nutritional management of patients undergoing peritoneal dialysis. In: Nolph KD, ed., Peritoneal Dialysis. Kluwer Academic Publishers, Dordrecht; 1989: 230–260.
    
23. 
    Lobbedez T, Lecouf A, Ficheux M, Henri P, de Ligny BH, Ryckelynck J-P. Is rapid initiation of peritoneal dialysis feasible in unplanned dialysis patients A single-centre experience. Nephrol Dial Transplant 2008; 23: 3290-3294.
    
24. 
    Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723–731.
    
25. 
    MacLeod A, Grant A, Donaldson C, et al. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. Health Technol Assess 1998;2(5):1-166.
    
26. 
    Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998;53(4):1061-7.
    
27. 
    McGregor SJ, Brock JH, Briggs JD, Junor BJ. Longitudinal study of peritoneal defence mechanisms in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int Peritoneal Dialysis International 1989;9:115-9.
    
28. 
    Mehrotra R, Chiu Y-W, Kalantar-Zadeh K, Vonesh E. The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney Int 2009; 76: 97-107.
    
29. 
    Michels WM, Verduijn M, Boeschoten EW, Dekker FW, Krediet RT. Similar survival on automated peritoneal dialysis and continuous ambulatory peritoneal dialysis in a large prospective cohort. Clin J Am Soc Nephrol 2009; 4: 943-949.
    
30. 
    Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2: 178–182.
    
31. 
    Mistry CD, Gokal R, Peers EM, and the MIDAS study group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46: 496-503.
    
32. 
    Mistry CD, Gokal R. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis: the role for ‘colloid’ osmosis. Clin Sci 1993; 85: 495–500.
    
33. 
    Mortier S, De Vriese AS, McLoughlin RM et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14: 1296–1306.
    
34. 
    Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13: 480–489.
    
35. 
    Navarro JF, Mora C, Macia M, Garcia J. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Perit Dial Int 1999; 19: 455–461.
    
36. 
    Nolph KD, Prowant B, Serkes KD et al. Multicentric evaluation of a new peritoneal dialysis solution with a high lactate and low magnesium concentration. Perit Dial Bull 1983; 3: 63–65.
    
37. 
    Povlsen JV, Ivarsen P. How to start late referred ESRD patient urgently on chronic APD Nephrol Dial Transplant 2006; 21 (Suppl 2): ii56-ii59
    
38. 
    Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, MacLeod AM. Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials Nephrol Dial Transplant 2007; 22: 2991-2998.
    
39. 
    Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988;34(3):404-11.
    
40. 
    Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bioincompatible solutions. Adv Ren Replace Ther 1998;5(3):179-84.
    
41. 
    Weinreich T, Passlick-Deetjen J, Ritz E, collaborators of the peritoneal dialysis multicenter study group. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. Am J Kidney Dis 1995; 25: 452–460.
    
42. 
    Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995; 15: 158–164.
    
43. 
    Wieslander AP, Andren AHG, Nilsson-Thorell C, Muscalu N, Kjellstrand PTT, Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro Perit Dial Int 1995; 15:348–352.
    
44. 
    Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13(2):470-9.